## **Core Concept**
The management of deep vein thrombosis (DVT) involves anticoagulation to prevent the progression of the clot, reduce the risk of pulmonary embolism, and minimize the risk of post-thrombotic syndrome. The choice of anticoagulant and the duration of therapy depend on several factors including the patient's risk factors for bleeding, renal function, and the presence of cancer.

## **Why the Correct Answer is Right**
The correct approach for managing DVT, especially in a postoperative patient, involves the initiation of anticoagulation therapy. **Low Molecular Weight Heparin (LMWH)** is often the preferred initial treatment in many cases, especially in cancer patients or those with reduced renal function, due to its predictable dose response and lower risk of heparin-induced thrombocytopenia compared to unfractionated heparin. For patients with DVT who are at high risk of bleeding or have significant renal impairment, LMWH is often chosen.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is blank and cannot be evaluated.
- **Option B:** This option is blank and cannot be evaluated.
- **Option D:** This option is blank and cannot be evaluated.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that anticoagulation for DVT typically involves a period of overlap with a vitamin K antagonist (like warfarin) or the use of direct oral anticoagulants (DOACs) like rivaroxaban, apixaban, or dabigatran for several months, depending on the patient's risk factors and the presence of any provoking factors. However, in the immediate postoperative period, especially in a recent surgical patient, LMWH may be preferred due to its safety profile and efficacy.

## **Correct Answer:** C.